Ask HopeStage to review this study with me
Leave your email and HopeStage can help you better understand this study.
Study reference: NCT05434156. HopeStage can help you review the study, but cannot decide medical eligibility.
Active Not RecruitingNCT05434156
ELE-101 Safety & Tolerability Study in Healthy Participants and people with Depression
This study is active but not recruiting. It focuses on depression and currently lists study information in the United Kingdom.
DepressionDrugFrom 18 Years to 65 Years
Key information made simple
This observational study is following people with depression to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information. Taking part may give some people access to ELE-101 with regular follow-up, but direct benefit is not guaranteed.
Your next step
The official record suggests in-person participation through a lab, with sites including MAC Clinical Research in Liverpool and MAC Clinical Research in Manchester. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually being able to understand the study and consent and matching the main diagnosis, while common reasons not to take part include active substance or alcohol problems that could affect the results and major medical issues that could make participation unsuitable. This is an early-stage study, which usually means a smaller group and a focus on learning how the approach behaves.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
- Sponsor
- Eleusis Therapeutics
- Sponsor type
- Biotech company
- Main activity
- medication or study treatment
- Intervention
- Not available
- Time commitment
- long follow-up or multiple visits
- Study phase
- Not available
- Enrollment
- Not available
- Recruitment status
- Active Not Recruiting
- Source
- Official registry link
Key study information
- Official title
- ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression
- Condition
- Healthy Volunteers; Major Depressive Disorder; Depression
- Study status
- Active Not Recruiting
- Sponsor / lead affiliation
- Eleusis Therapeutics
- Location / country
- United Kingdom
- Registry
- ClinicalTrials.gov
- External trial ID
- NCT05434156
Why this study may matter
This study may matter because it adds public evidence around depression. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.
For you
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in United Kingdom.
Registry reference
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
- Official title
- ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression
- Source
- ClinicalTrials.gov
- Official registry link
- Open official registry
- External trial ID
- NCT05434156
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is ELE-101 Safety & Tolerability Study in Healthy Participants and people with Depression?
This study is exploring medication or study treatment for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.
Who is behind this study, and what type of sponsor is it?
This study is sponsored by Eleusis Therapeutics. Based on the sponsor name or official registry information, it appears to be a biotech company. You should verify the details in the official registry record.
What does participation involve, what phase is it, and what should I ask about safety?
This study may involve medication or study treatment, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Where can I verify the study details?
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me